Empresa Algernon Pharmaceuticals Inc.
Acciones
AGN
CA01559R4008
Biotecnología e investigación médica
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
0,125 CAD | +13,64 % | +13,64 % | +92,31 % |
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chris Moreau
CEO | Chief Executive Officer | 59 | 01/03/18 |
James Kinley
DFI | Director of Finance/CFO | 45 | 01/12/21 |
Chief Operating Officer | 41 | 01/03/21 | |
Ahmad Khalil
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Harry Bloomfield
CHM | Chairman | 79 | 08/09/21 |
Chris Moreau
CEO | Chief Executive Officer | 59 | 01/03/18 |
Mark Williams
BRD | Director/Board Member | 52 | 22/09/21 |
James Kinley
DFI | Director of Finance/CFO | 45 | 01/12/21 |
Raj Attariwala
BRD | Director/Board Member | 55 | 26/10/15 |
Howard Gutman
BRD | Director/Board Member | - | 28/02/22 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 21 840 722 | 21 665 319 ( 99,20 %) | 0 | 99,20 % |
Información de la empresa
Algernon Pharmaceuticals, Inc.
601 West Broadway Street Suite 400
V5Z 4C2, Vancouver
+604-398-4175
http://www.algernonpharmaceuticals.comSector
Ganancias trimestrales - Tasa de sorpresa
Varia. 1 de ene. | Capi. | |
---|---|---|
+92,31 % | 1,98 M | |
+3,91 % | 109 mil M | |
+10,87 % | 105 mil M | |
+1,28 % | 22,25 mil M | |
-13,14 % | 22,09 mil M | |
-7,05 % | 18,68 mil M | |
-38,36 % | 17,58 mil M | |
-10,66 % | 16,85 mil M | |
+3,75 % | 13,76 mil M | |
+36,70 % | 12,46 mil M |
- Bolsa de valores
- Acciones
- Acción AGN
- Empresa Algernon Pharmaceuticals Inc.